Hormone replacement therapy in postmenopausal women with Alzheimer's disease: A randomized, prospective study

Fertility and Sterility

Volumn 79, Issue 2, 2003, Pages 274-280

  Yoon, Byung Koo ^a,b   Kim, Doh Kwan ^a,b   Kang, Yeonwook ^a,b   Kim, Jong Won ^a,b   Shin, Myung Hee ^a,b   Na, Duk L ^a,b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Hallym University   (South Korea)

Author keywords

Alzheimer's disease; Estrogens; Hormone replacement therapy; Progesterone; Tacrine

Indexed keywords

APOLIPOPROTEIN E; CONJUGATED ESTROGEN; PROGESTERONE; TACRINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; FEMALE; GENOTYPE; HAMILTON SCALE; HORMONE SUBSTITUTION; HUMAN; LEARNING TEST; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MENTAL TEST; MINI MENTAL STATE EXAMINATION; MOOD; PERSONALITY TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UTERUS;

ALZHEIMER DISEASE; APOLIPOPROTEINS E; BODY CONSTITUTION; CHOLINESTERASE INHIBITORS; ESTROGEN REPLACEMENT THERAPY; FEMALE; GENOTYPE; HUMANS; MENARCHE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSTMENOPAUSE; PROSPECTIVE STUDIES; TACRINE;

EID: 0037309386     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(02)04666-6     Document Type: Article

References (43)

1. Qizilbash N., Whitehead A., Higgins J., Wilcock G., Schneider L., Farlow M., et al. Cholinesterase inhibition for Alzheimer's disease a meta-analysis of the tacrine trials . JAMA. 280:1998;1777-1782.
2. MacGowan S.H., Wilcock G.K., Scott M. Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease. Int J Geriatr Psychiatry. 13:1998;625-630.
3. Tang M.X., Jacobs D., Stern Y., Marder K., Schofield P., Gurland B., et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 348:1996;429-432.
4. Kawas C., Resnick S., Morrison A., Brookmeyer R., Corrada M., Zonderman A., et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease the Baltimore Longitudinal Study of Aging . Neurology. 48:1997;1517-1521.
5. Baldereschi M., Di Carlo A., Lepore V., Bracco L., Maggi S., Grigoletto F., et al. Estrogen-replacement therapy and Alzheimer's disease in the Italian longitudinal study on aging. Neurology. 50:1998;996-1002.
6. Waring S.C., Rocca W.A., Petersen R.C., O'Brien P.C., Tangalos E.G., Kokmen E. Postmenopausal estrogen replacement therapy and risk of AD. Neurology. 52:1999;965-970.
7. Inestrosa N.C., Marzolo M.P., Bonnefont A.B. Cellular and molecular basis of estrogen's neuroprotection. Potential relevance for Alzheimer's disease. Mol Neurobiol. 17:1998;73-86.
8. Fillit H., Weinreb H., Cholst I., Luine V., McEwen B., Amador R., et al. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology. 11:1986;337-345.
9. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease . Neurology. 34:1984;939-944.
10. Hughes C.P., Berg L., Danziger W.L., Coben L.A., Martin R.L. A new clinical scale for the staging of dementia. Br J Psychiatry. 140:1982;566-572.
11. Kang Y., Na D.L., Hahn S. A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients. J Kor Neurol Assoc. 15:1997;300-307.
12. Brandt J. The Hopkins Verbal Learning Test development of a new memory test with sex equivalent forms . Clin Neuropsychol. 5:1991;125-142.
13. Kim H., Na D.L. Normative data on the Korean version of the Boston Naming Test. J Clin Exp Neuropsychol. 21:1999;127-133.
14. Kang Y., Chin J.H., Na D.L., Lee J., Park J.S. A normative study of the Korean version of Controlled Oral Word Association Test (COWAT) in the elderly. Kor J Clin Psychol. 19:2000;385-392.
15. Jung I.K., Kwak D.I., Shin D.K., Lee M.S., Lee H.S., Kim J.Y. A reliability and validity study of Geriatric Depression Scale. J Korean Neuropsychiatr Assoc. 36:1997;103-112.
16. Hamilton M. Development of a rating scale for primary depressive illness. Br J Clin Psychol. 6:1967;278-296.
17. Lawton M.P., Brody E.M. Assessment of older people self-maintaining and instrumental activities of daily living . Gerontologist. 9:1969;179-186.
18. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 31:1990;545-548.
19. Farlow M.R., Lahiri D.K., Poirier J., Davignon J., Schneider L., Hui S.L. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology. 50:1998;669-677.
20. Heikkinen A.M., Niskanen L., Ryynänen M., Komulainen M.H., Tuppurainen M.T., Parviainen M., et al. Is the response of serum lipids and lipoproteins to postmenopausal hormone replacement therapy modified by ApoE genotype? Arterioscler Thromb Vasc Biol. 19:1999;402-407.
21. Rogers S.L., Farlow M.R., Doody R.S., Mohs R., Friedhoff L.T. A 24-week, double-blind, placebo-controlled trial of donepazil in patients with Alzheimer's disease. Neurology. 50:1998;136-145.
22. Rosler M., Anand R., Cicin-Sain A., Gauthier S., Agid Y., Dal-Bianco P., et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease international randomized controlled trial . BMJ. 318:1999;633-638.
23. Knopman D., Kahn J., Miles S. Clinical research designs for emerging treatments for Alzheimer disease moving beyond placebo-controlled trials . Arch Neurol. 55:1998;1425-1429.
24. Honjo H., Ogino Y., Tanaka K., Urabe M., Kashiwagi T., Ishihara S., et al. An effect of conjugated estrogen to cognitive impairment in women with senile dementia-Alzheimer's type a placebo-controlled, double-blind study . J Jpn Menopause Soc. 1:1993;167-171.
25. Asthana S., Craft S., Baker L.D., Raskind M.A., Birnbaum R.S., Lofgreen C.P., et al. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease results of a placebo-controlled, double-blind, pilot study . Psychoneuroendocrinology. 24:1999;657-677.
26. Asthana S., Baker L.D., Craft S., Stanczyk F.Z., Veith R.C., Raskind M.A., et al. High-dose estradiol improves cognition for women with AD results of a randomized study . Neurology. 57:2001;605-612.
27. Henderson V.W., Paganini-Hill A., Miller B.L., Elble R.J., Reyes P.F., Shoupe D., et al. Estrogen for Alzheimer's disease in women randomized, double-blind, placebo-controlled trial . Neurology. 54:2000;295-301.
28. Mulnard R.A., Cotman C.W., Kawas C., van Dyck C.H., Sano M., Doody R., et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease. JAMA. 283:2000;1007-1015.
29. Kinsley C.H., Madonia L., Gifford G.W., Tureski K., Griffin G.R., Lowry C., et al. Motherhood improves learning and memory. Nature. 402:1999;137-138.
30. Sherwin B.B. Estrogenic effects on memory in women. Ann N Y Acad Sci. 743:1994;213-231.
31. Natale V., Albertazzi P., Zini M., Di Micco R. Exploration of cyclical changes in memory and mood in postmenopausal women taking sequential combined oestrogen and progestogen preparations. Br J Obstet Gynecol. 108:2001;286-290.
32. Rice M.M., Graves A.B., McCurry S.M., Gibbons L.E., Bowen J.D., McCormick W.C., et al. Postmenopausal estrogen and estrogen-progestin use and 2-year rate of cognitive change in a cohort of older Japanese American women The Kame Project . Arch Intern Med. 160:2000;1641-1649.
33. Gould E., Woolley C.S., Frankfurt M., McEwen B.S. Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood. J Neurosci. 10:1990;1286-1291.
34. Gibbs R.B. Fluctuations in relative levels of choline acetyl transferase mRNA in different regions of the rat basal forebrain across the estrous cycle effects of estrogen and progesterone . J Neurosci. 16:1996;1049-1055.
35. Gibbs R.B. Levels of trkA and BDNF mRNA, but not NGF mRNA, fluctuate across the estrous cycle and increase in response to acute hormone replacement. Brain Res. 787:1998;259-268.
36. Goodman Y., Bruce A.J., Cheng B., Mattson M.P. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid β-peptide toxicity in hippocampal neurons. J Neurochem. 66:1996;1836-1844.
37. Greendale G.A., Reboussin B.A., Hogan P., Barnabei V.M., Shumaker S., Johnson S., et al. Symptom relief and side effects of postmenopausal hormones results from the postmenopausal estrogen/progestin interventions trial . Obstet Gynecol. 92:1998;982-988.
38. Grey A., Cundy T., Evans M., Reid I. Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late post-menopausal women. Clin Endocrinol (Oxf). 44:1996;293-296.
39. Regestein Q. Menopausal progesterone replacement and sleep quality. Menopause. 8:2001;3-4.
40. Poirier J., Delisle M.C., Quirion R., Aubert I., Farlow M., Lahiri D., et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA. 92:1995;12260-12264.
41. Craft S., Teri L., Edland S.D., Kukull W.A., Schellenberg G., McCormick W.C., et al. Accelerated decline in apolipoprotein E-ε4 homozygotes with Alzheimer's disease. Neurology. 51:1998;149-153.
42. Raskind M.A., Sadowsky C.H., Sigmund W.R., Beitler P.J., Auster S.B. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer's disease. Arch Neurol. 54:1997;836-840.
43. Yaffe K., Blackwell T., Gore R., Sands L., Reus V., Browner W.S. Depressive symptoms and cognitive decline in nondemented elderly women a prospective study . Arch Gen Psychiatry. 56:1999;425-430.